Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kerri Pillar

Nurse Practitioner, Primary Care Victoria, TX Nurse Practitioner

NPI 1619406592 CMS profile 2822122

606 E Nueces St, Victoria, TX 77901

Open in the dashboard

General payments

$2,857

157 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kerri Pillar of Victoria, TX is reported in the CMS Open Payments database as having received $2,857 across 157 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $322 18
2024 General $505 28
2023 General $702 39
2022 General $591 29
2021 General $738 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kerri Pillar
  • Nurse Practitioner, Primary Care median
  • Middle half of Nurse Practitioner, Primary Care
  • National median

In program year 2025, general payments to Kerri Pillar were reported at $322. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.

Show as a table
Year Kerri Pillar Nurse Practitioner, Primary Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $738 $137 $39–$445 $132
2022 $591 $139 $44–$421 $149
2023 $702 $163 $53–$481 $160
2024 $505 $176 $54–$511 $164
2025 $322 $169 $51–$499 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $338 25 payments
  2. Novo Nordisk Inc $305 18 payments
  3. Astellas Pharma US Inc $245 11 payments
  4. AbbVie, Inc. $220 13 payments
  5. Amgen Inc. $203 14 payments
  6. GlaxoSmithKline, LLC. $197 8 payments
  7. AstraZeneca Pharmaceuticals LP $179 10 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $175 6 payments
  9. Pfizer Inc. $137 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $118 3 payments
  11. Other $740 42 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,744 155 payments
  2. Education $114 2 payments
Products named General payments · program years 2021–2025
  1. NURTEC ODT Primary Care $209 7 payments
  2. VRAYLAR $168 10 payments
  3. Wegovy $157 9 payments
  4. MOUNJARO $140 12 payments
  5. NURTEC ODT Pain $137 7 payments
  6. Repatha $136 8 payments
  7. Ozempic $130 8 payments
  8. ZAVZPRET $123 6 payments
  9. TRELEGY ELLIPTA $121 7 payments
  10. RYBELSUS $110 7 payments
  11. Other $1,975 115 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

3,888

Median for Nurse Practitioner: 389

Drug cost

$501,623

Median for Nurse Practitioner: $21,885

Branded share of claims

23%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 180 $194,305
Ozempic Semaglutide Brand 58 $66,577
Trulicity Dulaglutide Brand 39 $38,358
Eliquis Apixaban Brand 39 $38,174
Januvia Sitagliptin Phosphate Brand 17 $27,431
Vascepa Icosapent Ethyl Brand 24 $23,846
Kerendia Finerenone Brand 20 $20,895
Farxiga Dapagliflozin Propanediol Brand 20 $16,059
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 12 $11,940
Repatha Sureclick Evolocumab Brand 15 $8,482

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$61,771

Of which drugs: $828

Medicare patients

152

Average age 73

Services billed

2,243

111 women, 41 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 41%
Ischemic heart disease 22%
Osteoporosis 19%
COPD 18%
Depression 18%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 14 14 $506
Injection, methylprednisolone acetate, 1 mg J1010 Office 14 1,080 $100

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $134
$134 — —
Wegovy
  • Novo Nordisk Inc $67
$67 — —
Veozah
  • Astellas Pharma US Inc $45
$45 — —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $29
$29 — —
Ozempic
  • Novo Nordisk Inc $23
$23 58 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

157 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record